-
2
-
-
79951575730
-
-
American Cancer Society, Atlanta, GA: American Cancer Society 2010
-
American Cancer Society. Cancer Facts and Figures 2010. Atlanta, GA: American Cancer Society; 2010.
-
(2010)
Cancer Facts and Figures
-
-
-
3
-
-
0030749321
-
Skeletal complications of malignancy
-
Coleman RE. Skeletal complications of malignancy. Cancer. 1997; 80(8 Suppl):1588-1594.
-
(1997)
Cancer
, vol.80
, Issue.8 SUPPL.
, pp. 1588-1594
-
-
Coleman, R.E.1
-
4
-
-
35048875471
-
Pathologic fractures correlate with reduced survival in patients with malignant bone disease
-
Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer. 2007;110(8):1860-1867.
-
(2007)
Cancer
, vol.110
, Issue.8
, pp. 1860-1867
-
-
Saad, F.1
Lipton, A.2
Cook, R.3
Chen, Y.M.4
Smith, M.5
Coleman, R.6
-
5
-
-
0037241535
-
In vitro and in vivo antitumor effects of bisphosphonates
-
Clezardin P, Fournier P, Boissier S, Peyruchaud O. In vitro and in vivo antitumor effects of bisphosphonates. Curr Med Chem. 2003;10(2): 173-180.
-
(2003)
Curr Med Chem
, vol.10
, Issue.2
, pp. 173-180
-
-
Clezardin, P.1
Fournier, P.2
Boissier, S.3
Peyruchaud, O.4
-
6
-
-
49949115926
-
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bonemineral density substudy
-
Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bonemineral density substudy. Lancet Oncol. 2008;9(9):840-849.
-
(2008)
Lancet Oncol
, vol.9
, Issue.9
, pp. 840-849
-
-
Gnant, M.1
Mlineritsch, B.2
Luschin-Ebengreuth, G.3
-
7
-
-
34250326616
-
Meta-analysis of clodronate and breast cancer survival
-
Ha TC, Li H. Meta-analysis of clodronate and breast cancer survival. Br J Cancer. 2007;96(12):1796-1801.
-
(2007)
Br J Cancer
, vol.96
, Issue.12
, pp. 1796-1801
-
-
Ha, T.C.1
Li, H.2
-
8
-
-
54249151531
-
Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer
-
Hershman DL, McMahon DJ, Crew KD, et al. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol. 2008;26(29): 4739-4745.
-
(2008)
J Clin Oncol
, vol.26
, Issue.29
, pp. 4739-4745
-
-
Hershman, D.L.1
McMahon, D.J.2
Crew, K.D.3
-
10
-
-
6844252283
-
Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group
-
Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol. 1998;16(2): 593-602.
-
(1998)
J Clin Oncol
, vol.16
, Issue.2
, pp. 593-602
-
-
Berenson, J.R.1
Lichtenstein, A.2
Porter, L.3
-
11
-
-
0035312469
-
Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases
-
Berenson JR, Rosen LS, Howell A, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer. 2001;91(7):1191-1200.
-
(2001)
Cancer
, vol.91
, Issue.7
, pp. 1191-1200
-
-
Berenson, J.R.1
Rosen, L.S.2
Howell, A.3
-
12
-
-
17144447171
-
Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases
-
Body JJ, Diel IJ, Lichinitser MR, et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol. 2003;14(9):1399-1405.
-
(2003)
Ann Oncol
, vol.14
, Issue.9
, pp. 1399-1405
-
-
Body, J.J.1
Diel, I.J.2
Lichinitser, M.R.3
-
13
-
-
1942501727
-
Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: Results from two randomised, placebo-controlled phase III studies
-
Body JJ, Diel IJ, Lichinitzer M, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer. 2004;90(6):1133-1137.
-
(2004)
Br J Cancer
, vol.90
, Issue.6
, pp. 1133-1137
-
-
Body, J.J.1
Diel, I.J.2
Lichinitzer, M.3
-
14
-
-
0031810467
-
Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: A double-blind placebo-controlled trial. Danish-Swedish co-operative study group
-
Brincker H, Westin J, Abildgaard N, et al. Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group. Br J Haematol. 1998;101(2):280-286.
-
(1998)
Br J Haematol
, vol.101
, Issue.2
, pp. 280-286
-
-
Brincker, H.1
Westin, J.2
Abildgaard, N.3
-
15
-
-
0042331464
-
A double-blind, placebocontrolled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial)
-
Dearnaley DP, Sydes MR, Mason MD, et al. A double-blind, placebocontrolled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst. 2003;95(17): 1300-1311.
-
(2003)
J Natl Cancer Inst
, vol.95
, Issue.17
, pp. 1300-1311
-
-
Dearnaley, D.P.1
Sydes, M.R.2
Mason, M.D.3
-
16
-
-
77957332677
-
Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): A double-blind, randomised controlled trial
-
Gimsing P, Carlson K, Turesson I, et al. Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial. Lancet Oncol. 2010;11(10): 973-982.
-
(2010)
Lancet Oncol
, vol.11
, Issue.10
, pp. 973-982
-
-
Gimsing, P.1
Carlson, K.2
Turesson, I.3
-
17
-
-
20644449488
-
Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: A randomized, placebo-controlled trial
-
Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol. 2005;23(15):3314-3321.
-
(2005)
J Clin Oncol
, vol.23
, Issue.15
, pp. 3314-3321
-
-
Kohno, N.1
Aogi, K.2
Minami, H.3
-
18
-
-
0032798648
-
Oral clodronate in breast cancer patients with bone metastases: A randomized study
-
Kristensen B, Ejlertsen B, Groenvold M, Hein S, Loft H, Mouridsen HT. Oral clodronate in breast cancer patients with bone metastases: a randomized study. J Intern Med. 1999;246(1):67-74.
-
(1999)
J Intern Med
, vol.246
, Issue.1
, pp. 67-74
-
-
Kristensen, B.1
Ejlertsen, B.2
Groenvold, M.3
Hein, S.4
Loft, H.5
Mouridsen, H.T.6
-
19
-
-
0026646339
-
Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group
-
Lahtinen R, Laakso M, Palva I, Virkkunen P, Elomaa I. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. Lancet. 1992;340(8827): 1049-1052.
-
(1992)
Lancet
, vol.340
, Issue.8827
, pp. 1049-1052
-
-
Lahtinen, R.1
Laakso, M.2
Palva, I.3
Virkkunen, P.4
Elomaa, I.5
-
20
-
-
0034162528
-
Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: Long term follow-up of two randomized, placebo-controlled trials
-
Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer. 2000; 88(5):1082-1090.
-
(2000)
Cancer
, vol.88
, Issue.5
, pp. 1082-1090
-
-
Lipton, A.1
Theriault, R.L.2
Hortobagyi, G.N.3
-
21
-
-
0031911183
-
A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults
-
McCloskey EV, MacLennan IC, Drayson MT, Chapman C, Dunn J, Kanis JA. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults. Br J Haematol. 1998;100(2):317-325.
-
(1998)
Br J Haematol
, vol.100
, Issue.2
, pp. 317-325
-
-
McCloskey, E.V.1
Maclennan, I.C.2
Drayson, M.T.3
Chapman, C.4
Dunn, J.5
Kanis, J.A.6
-
22
-
-
0036570071
-
Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma
-
Menssen HD, Sakalova A, Fontana A, et al. Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J Clin Oncol. 2002;20(9):2353-2359.
-
(2002)
J Clin Oncol
, vol.20
, Issue.9
, pp. 2353-2359
-
-
Menssen, H.D.1
Sakalova, A.2
Fontana, A.3
-
23
-
-
0027531814
-
Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer
-
Paterson AH, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol. 1993;11(1):59-65.
-
(1993)
J Clin Oncol
, vol.11
, Issue.1
, pp. 59-65
-
-
Paterson, A.H.1
Powles, T.J.2
Kanis, J.A.3
McCloskey, E.4
Hanson, J.5
Ashley, S.6
-
24
-
-
0035463593
-
Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial
-
Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001;7(5):377-387.
-
(2001)
Cancer J
, vol.7
, Issue.5
, pp. 377-387
-
-
Rosen, L.S.1
Gordon, D.2
Kaminski, M.3
-
25
-
-
10744233021
-
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, multicenter, comparative trial
-
Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003;98(8):1735-1744.
-
(2003)
Cancer
, vol.98
, Issue.8
, pp. 1735-1744
-
-
Rosen, L.S.1
Gordon, D.2
Kaminski, M.3
-
26
-
-
0042914647
-
Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial - the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group
-
Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial - the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003;21(16):3150-3157.
-
(2003)
J Clin Oncol
, vol.21
, Issue.16
, pp. 3150-3157
-
-
Rosen, L.S.1
Gordon, D.2
Tchekmedyian, S.3
-
27
-
-
0037009822
-
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma
-
Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94(19):1458-1468.
-
(2002)
J Natl Cancer Inst
, vol.94
, Issue.19
, pp. 1458-1468
-
-
Saad, F.1
Gleason, D.M.2
Murray, R.3
-
28
-
-
0642337996
-
Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer
-
Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol. 2003;21(23):4277-4284.
-
(2003)
J Clin Oncol
, vol.21
, Issue.23
, pp. 4277-4284
-
-
Small, E.J.1
Smith, M.R.2
Seaman, J.J.3
Petrone, S.4
Kowalski, M.O.5
-
29
-
-
17444435152
-
Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases
-
Tubiana-Hulin M, Beuzeboc P, Mauriac L, et al. Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bull Cancer. 2001;88(7):701-707.
-
(2001)
Bull Cancer
, vol.88
, Issue.7
, pp. 701-707
-
-
Tubiana-Hulin, M.1
Beuzeboc, P.2
Mauriac, L.3
-
30
-
-
79952648900
-
-
Zometa [prescribing information], NJ: Novartis Pharmaceuticals Corporation
-
Zometa [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2009.
-
(2009)
East Hanover
-
-
-
31
-
-
79952674051
-
-
Aredia [prescribing information], NJ: Novartis Pharmaceuticals Corporation
-
Aredia [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2008.
-
(2008)
East Hanover
-
-
-
32
-
-
77953225071
-
-
Xgeva [prescribing information], CA: Amgen Inc
-
Xgeva [prescribing information]. Thousand Oaks, CA: Amgen Inc.; 2010.
-
(2010)
Thousand Oaks
-
-
-
33
-
-
79952684496
-
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology
-
Published 2010. Updated December 6, 2010. Accessed January 5, 2011
-
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer V.2.2011. www.nccn.org. Published 2010. Updated December 6, 2010. Accessed January 5, 2011.
-
(2011)
Breast Cancer
, vol.2
-
-
-
34
-
-
28844439011
-
Anti-tumour activity of zoledronic acid
-
Clezardin P. Anti-tumour activity of zoledronic acid. Cancer Treat Rev. 2005;31(Suppl 3):1-8.
-
(2005)
Cancer Treat Rev
, vol.31
, Issue.SUPPL. 3
, pp. 1-8
-
-
Clezardin, P.1
-
35
-
-
72849140888
-
Bisphosphonates in the prevention of disease recurrence: Current results and ongoing trials
-
Gnant M. Bisphosphonates in the prevention of disease recurrence: current results and ongoing trials. Curr Cancer Drug Targets. 2009;9(7): 824-833.
-
(2009)
Curr Cancer Drug Targets
, vol.9
, Issue.7
, pp. 824-833
-
-
Gnant, M.1
-
36
-
-
52049103847
-
The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance
-
Meads MB, Hazlehurst LA, Dalton WS. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res. 2008;14(9):2519-2526.
-
(2008)
Clin Cancer Res
, vol.14
, Issue.9
, pp. 2519-2526
-
-
Meads, M.B.1
Hazlehurst, L.A.2
Dalton, W.S.3
-
37
-
-
19944432878
-
Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors
-
Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst. 2005;97(1):59-69.
-
(2005)
J Natl Cancer Inst
, vol.97
, Issue.1
, pp. 59-69
-
-
Brown, J.E.1
Cook, R.J.2
Major, P.3
-
38
-
-
24644479228
-
Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid
-
Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol. 2005;23(22):4925-4935.
-
(2005)
J Clin Oncol
, vol.23
, Issue.22
, pp. 4925-4935
-
-
Coleman, R.E.1
Major, P.2
Lipton, A.3
-
39
-
-
35548960086
-
Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity
-
Lipton A, Cook RJ, Major P, Smith MR, Coleman RE. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist. 2007;12(9): 1035-1043.
-
(2007)
Oncologist
, vol.12
, Issue.9
, pp. 1035-1043
-
-
Lipton, A.1
Cook, R.J.2
Major, P.3
Smith, M.R.4
Coleman, R.E.5
-
40
-
-
47149118386
-
Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid
-
Lipton A, Cook R, Saad F, et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer. 2008;113(1):193-201.
-
(2008)
Cancer
, vol.113
, Issue.1
, pp. 193-201
-
-
Lipton, A.1
Cook, R.2
Saad, F.3
-
41
-
-
77955457605
-
A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer
-
Zaghloul MS, Boutrus R, El-Hossieny H, Kader YA, El-Attar I, Nazmy M. A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. Int J Clin Oncol. 2010; 15(4):382-389.
-
(2010)
Int J Clin Oncol
, vol.15
, Issue.4
, pp. 382-389
-
-
Zaghloul, M.S.1
Boutrus, R.2
El-Hossieny, H.3
Kader, Y.A.4
El-Attar, I.5
Nazmy, M.6
-
42
-
-
36248938315
-
Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma
-
Aviles A, Nambo MJ, Neri N, Castaneda C, Cleto S, Huerta-Guzman J. Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Med Oncol. 2007;24(2):227-230.
-
(2007)
Med Oncol
, vol.24
, Issue.2
, pp. 227-230
-
-
Aviles, A.1
Nambo, M.J.2
Neri, N.3
Castaneda, C.4
Cleto, S.5
Huerta-Guzman, J.6
-
43
-
-
78650174738
-
National Cancer Research Institute Haematological Oncology Clinical Study Group. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): A randomised controlled trial
-
Morgan GJ, Davies FE, Gregory WM, et al; National Cancer Research Institute Haematological Oncology Clinical Study Group. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet. 2010;376(9757):1989-1999.
-
(2010)
Lancet
, vol.376
, Issue.9757
, pp. 1989-1999
-
-
Morgan, G.J.1
Davies, F.E.2
Gregory, W.M.3
-
44
-
-
0023235009
-
Ovarian function and adjuvant chemotherapy for early breast cancer
-
Padmanabhan N, Wang DY, Moore JW, Rubens RD. Ovarian function and adjuvant chemotherapy for early breast cancer. Eur J Cancer Clin Oncol. 1987;23(6):745-748.
-
(1987)
Eur J Cancer Clin Oncol
, vol.23
, Issue.6
, pp. 745-748
-
-
Padmanabhan, N.1
Wang, D.Y.2
Moore, J.W.3
Rubens, R.D.4
-
45
-
-
0034037097
-
Osteoporosis due to cancer treatment: Pathogenesis and management
-
Pfeilschifter J, Diel IJ. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol. 2000;18(7):1570-1593.
-
(2000)
J Clin Oncol
, vol.18
, Issue.7
, pp. 1570-1593
-
-
Pfeilschifter, J.1
Diel, I.J.2
-
46
-
-
33947539707
-
Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: A report from the Austrian Breast and Colorectal Cancer Study Group
-
Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol. 2007;25(7):820-828.
-
(2007)
J Clin Oncol
, vol.25
, Issue.7
, pp. 820-828
-
-
Gnant, M.F.1
Mlineritsch, B.2
Luschin-Ebengreuth, G.3
-
47
-
-
41949094767
-
Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230
-
Eastell R, Adams JE, Coleman RE, et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol. 2008;26(7):1051-1057.
-
(2008)
J Clin Oncol
, vol.26
, Issue.7
, pp. 1051-1057
-
-
Eastell, R.1
Adams, J.E.2
Coleman, R.E.3
-
48
-
-
60549097419
-
Endocrine therapy plus zoledronic acid in premenopausal breast cancer
-
Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009; 360(7):679-691.
-
(2009)
N Engl J Med
, vol.360
, Issue.7
, pp. 679-691
-
-
Gnant, M.1
Mlineritsch, B.2
Schippinger, W.3
-
49
-
-
84858230560
-
Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive early breast cancer
-
Mature results from ABCSG-12, ASCO); June 4-8, 2010; Chicago, IL. Abstract 533
-
Gnant M, Mlineritsch B, Stoeger H, et al. Mature results from ABCSG-12: Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive early breast cancer. Presented at 46th Annual Meeting of the American Society of Clinical Oncology (ASCO); June 4-8, 2010; Chicago, IL. Abstract 533.
-
Presented At 46th Annual Meeting of the American Society of Clinical Oncology
-
-
Gnant, M.1
Mlineritsch, B.2
Stoeger, H.3
-
50
-
-
51649118688
-
Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo
-
Ottewell PD, Deux B, Monkkonen H, et al. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo. Clin Cancer Res. 2008;14(14):4658-4666.
-
(2008)
Clin Cancer Res
, vol.14
, Issue.14
, pp. 4658-4666
-
-
Ottewell, P.D.1
Deux, B.2
Monkkonen, H.3
-
51
-
-
77952305169
-
Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: An open label, randomised, phase 2 trial
-
Aft R, Naughton M, Trinkaus K, et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol. 2010; 11(5):421-428.
-
(2010)
Lancet Oncol
, vol.11
, Issue.5
, pp. 421-428
-
-
Aft, R.1
Naughton, M.2
Trinkaus, K.3
-
52
-
-
79952649231
-
ZOL on disseminated tumor cells (DTC) in the bone marrow (BM) of women with early-stage breast cancer (ESBC): Updated results
-
Presented At 46th Annual Meeting of the American Society of Clinical Oncology; June 4-8 Chicago, IL. Abstract
-
Greenberg S, Park JW, Melisko ME, et al. Effect of adjuvant zoledronic acid (ZOL) on disseminated tumor cells (DTC) in the bone marrow (BM) of women with early-stage breast cancer (ESBC): updated results. Presented at 46th Annual Meeting of the American Society of Clinical Oncology; June 4-8, 2010; Chicago, IL. Abstract 1002.
-
(1002)
Effect of adjuvant zoledronic acid
-
-
Greenberg, S.1
Park, J.W.2
Melisko, M.E.3
-
53
-
-
77954572691
-
Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer
-
Rack B, Juckstock J, Genss EM, et al. Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer. Anticancer Res. 2010;30(5):1807-1813.
-
(2010)
Anticancer Res
, vol.30
, Issue.5
, pp. 1807-1813
-
-
Rack, B.1
Juckstock, J.2
Genss, E.M.3
-
54
-
-
79952646544
-
Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients
-
San Antonio, TX. Abstract
-
Solomayer EF, Gebauer G, Hirnle P, et al. Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients. Presented at 31st Annual San Antonio Breast Cancer Symposium; December 10-14, 2008; San Antonio, TX. Abstract 2048.
-
(2048)
Presented At 31st Annual San Antonio Breast Cancer Symposium
-
-
Solomayer, E.F.1
Gebauer, G.2
Hirnle, P.3
-
55
-
-
13944259758
-
The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence
-
Janni W, Rack B, Schindlbeck C, et al. The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence. Cancer. 2005;103(5):884-891.
-
(2005)
Cancer
, vol.103
, Issue.5
, pp. 884-891
-
-
Janni, W.1
Rack, B.2
Schindlbeck, C.3
-
56
-
-
34547743433
-
Prognostic relevance of disseminated tumor cells in the bone marrow and biological factors of 265 primary breast carcinomas
-
Schindlbeck C, Kampik T, Janni W, et al. Prognostic relevance of disseminated tumor cells in the bone marrow and biological factors of 265 primary breast carcinomas. Breast Cancer Res. 2005;7(6): R1174-R1185.
-
(2005)
Breast Cancer Res
, vol.7
, Issue.6
-
-
Schindlbeck, C.1
Kampik, T.2
Janni, W.3
-
57
-
-
61349156290
-
Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow
-
20s. Abstract 559
-
Lin AY, Park JW, Scott J, et al. Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow. J Clin Oncol. 2008;26(Suppl):20s. Abstract 559.
-
(2008)
J Clin Oncol
, vol.26
, Issue.SUPPL
-
-
Lin, A.Y.1
Park, J.W.2
Scott, J.3
-
58
-
-
77949541181
-
Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: Evidence of synergistic interaction
-
Neville-Webbe HL, Coleman RE, Holen I. Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction. Br J Cancer. 2010;102(6):1010-1017.
-
(2010)
Br J Cancer
, vol.102
, Issue.6
, pp. 1010-1017
-
-
Neville-Webbe, H.L.1
Coleman, R.E.2
Holen, I.3
-
59
-
-
77954580167
-
Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study
-
Eidtmann H, de Boer R, Bundred N, et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol. 2010; 21(11):2188-2194.
-
(2010)
Ann Oncol
, vol.21
, Issue.11
, pp. 2188-2194
-
-
Eidtmann, H.1
de Boer, R.2
Bundred, N.3
-
60
-
-
78649241430
-
Postmenopausal women with early breast cancer receiving adjuvant letrozole
-
Zoledronic acid prevents aromatase inhibitor-associated bone loss in, E-ZO-FAST 36-month follow-up. Presented at, October 8-10, 2009; San Francisco, CA. Abstract 213
-
Llombart A, Frassoldati A, Paija O, et al. Zoledronic acid prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: E-ZO-FAST 36-month follow-up. Presented at 2009 ASCO Breast Cancer Symposium; October 8-10, 2009; San Francisco, CA. Abstract 213.
-
(2009)
ASCO Breast Cancer Symposium
-
-
Llombart, A.1
Frassoldati, A.2
Paija, O.3
-
61
-
-
79952676069
-
-
a 24-month integrated follow-up of the Z-FAST/ZO-FAST trials. Presented at 11th St. Gallen Breast Cancer Conference; March 11-14, 2009; St. Gallen, Switzerland. Abstract 132
-
Frassoldati A, Brufsky A, Bundred N, et al. Effect of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: a 24-month integrated follow-up of the Z-FAST/ZO-FAST trials. Presented at 11th St. Gallen Breast Cancer Conference; March 11-14, 2009; St. Gallen, Switzerland. Abstract 132.
-
(2009)
Effect of Zoledronic Acid In Postmenopausal Women With Early Breast Cancer Receiving Adjuvant Letrozole
-
-
Frassoldati, A.1
Brufsky, A.2
Bundred, N.3
-
62
-
-
67649804881
-
Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results
-
Brufsky AM, Bosserman LD, Caradonna RR, et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer. 2009;9(2):77-85.
-
(2009)
Clin Breast Cancer
, vol.9
, Issue.2
, pp. 77-85
-
-
Brufsky, A.M.1
Bosserman, L.D.2
Caradonna, R.R.3
-
63
-
-
79952680759
-
-
the ZO-FAST study 5-year final follow-up. Presented at 33rd Annual San Antonio Breast Cancer Symposium; December 8-12, 2010; San Antonio, TX. Poster P5-11-01
-
de Boer R, Bundred N, Eidtmann H, et al. The effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: the ZO-FAST study 5-year final follow-up. Presented at 33rd Annual San Antonio Breast Cancer Symposium; December 8-12, 2010; San Antonio, TX. Poster P5-11-01.
-
The Effect of Zoledronic Acid On Aromatase Inhibitor-associated Bone Loss In Postmenopausal Women With Early Breast Cancer Receiving Adjuvant Letrozole
-
-
de Boer, R.1
Bundred, N.2
Eidtmann, H.3
-
64
-
-
79952690872
-
-
Z-FAST, ZO-FAST, and E-ZO-FAST. Presented at 32nd Annual San Antonio Breast Cancer Symposium; December 9-13, 2009; San Antonio, TX. Abstract 4082
-
Coleman R, Bundred N, de Boer R, et al. Impact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST. Presented at 32nd Annual San Antonio Breast Cancer Symposium; December 9-13, 2009; San Antonio, TX. Abstract 4082.
-
Impact of Zoledronic Acid In Postmenopausal Women With Early Breast Cancer Receiving Adjuvant Letrozole
-
-
Coleman, R.1
Bundred, N.2
de Boer, R.3
-
65
-
-
79952646205
-
-
The AZURE trial (BIG 01/04). Presented at 33rd Annual San Antonio Breast Cancer Symposium; December 8-12, 2010; San Antonio, TX. Abstract S4-S5
-
Coleman RE, Thorpe HC, Cameron D, et al. Adjuvant treatment with zoledronic acid in stage II/III breast cancer. The AZURE trial (BIG 01/04). Presented at 33rd Annual San Antonio Breast Cancer Symposium; December 8-12, 2010; San Antonio, TX. Abstract S4-S5.
-
Adjuvant Treatment With Zoledronic Acid In Stage II/III Breast Cancer
-
-
Coleman, R.E.1
Thorpe, H.C.2
Cameron, D.3
-
66
-
-
77950370156
-
The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: Exploratory evidence for direct anti-tumour activity in breast cancer
-
Coleman RE, Winter MC, Cameron D, et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer. 2010;102:1099-1105.
-
(2010)
Br J Cancer
, vol.102
, pp. 1099-1105
-
-
Coleman, R.E.1
Winter, M.C.2
Cameron, D.3
|